Fw: e-Newsletter for Friday, April 6, 2012

[Guest guest]

From: "HIVandHepatitis.com" <newsletter@...>Date: Fri, 6 Apr 2012 15:48:36 -0400 (EDT)<nelsonvergel@...>Reply newsletter@...Subject: e-Newsletter for Friday, April 6, 2012Having trouble viewing this email?Click here e-Newsletter for Friday, April 6, 2012 Complete Coverage of the 2012 Conferenceon Retroviruses and Opportunistic Infections New HIV Drugs HIV Drug Development News from CROI 2012 4-in-1 Elvitegravir Quad Pill Matches Efavirenz and Atazanavir Combos New Integrase Inhibitor Dolutegravir Still Potent and Well-Tolerated at 96 Weeks Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation Phase 3 Trials Now Testing HCV Drug TMC435 in Genotype 1 Non-responders and Genotype 4 Patients HIV Treatment How Detrimental Is Low but Detectable HIV Viral Load? San Francisco Early Treatment Policy Linked to Lower Viral Load, Higher CD4 Count Infants with HIV Who Receive Early ART Can Safely Stop Treatment HIV Cure Research Zinc Finger HIV Gene Therapy Moves Ahead Vorinostat -- A First Step on the Road Towards a Cure for HIV HIV Cure Research -- A New Era of Treatment HIV Prevention The Real Life Challenge of HIV Treatment as Prevention Studies Advance Development of Rectal Gel and Vaginal Ring Microbicides for HIV Prevention Drug Levels Predict Efficacy in PrEP Trials, Showing Importance of Adherence Final Partners PrEP Results Confirm Efficacy of Oral Antiretrovirals for HIV Prevention Hormonal Contraception May Raise HIV Risk for Women, but Uncertainty Remains HIV-Related Conditions and Complications Community-wide Isoniazid Prevention Did Not Improve TB Control in South African Mines Elevated Blood Pressure Linked to Heart Attack Risk in HIV+ People Metformin, Statins, and ACE Inhibitors May Reduce Cardiovascular Risk of People with HIV HIV Brain Impairment: Who Gets It, and Why? Electrocautery Superior to Imiquimod or 5-Fluorouracil for Treatment of Anal Neoplasia Uncontrolled HIV Linked to Faster Lung Function Decline HIV Basic Science Broadly Neutralizing Antibodies Can Help Fight HIV HIV Superinfections May Happen as Often as First Infections HIV Epidemiology U.S. Black Women Have Higher Rates of HIV Infection and AIDS Death PEPFAR Funding Linked to Lower Death Rate from All Causes in Africa Hepatitis B and HIV/HBV Coinfection Detectable HIV Raises Risk of Incomplete Hepatitis B Suppression Long-term Tenofovir Promotes HBsAg Decline in HIV/HBV Coinfected People Hepatitis C and HIV/HCV Coinfection ART Liver Toxicity is Lower with Modern Regimens, but Still a Risk for HIV/HCV Coinfected HIV Treatment May Reduce Mother-to-Child Hepatitis C Transmission HIV/HCV Coinfection News from CROI 2012 HIV/HCV Positive People Need Ribavirin for Optimal Treatment of Acute Hepatitis C Studies Look at Interactions Between New Hepatitis C Drugs and HIV Antiretrovirals Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals are Minimal or Manageable GS-7977/Ribavirin Rapidly Suppresses HCV, but Most Patients Relapse after Stopping Treatment New Hepatitis C Drugs in Clinical Practice Telaprevir and Boceprevir Improve Sustained Response Rates in HIV/HCV Coinfected Patients New Hepatitis C Drugs in Clinical Practice What new data presented at CROI will influence theway clinicians care for their HIV/AIDS patients? To access this educational activity and receive(1) CME/CE credit, please click here or the button below. The certified CME/CE Talking Slides Update provides independent coverage by Rush University Medical Center of the 19th Conference on Retroviruses and Opportunistic Infections (CROI) held in Seattle, Washington, March 5-8, 2012. During this conference many issues were addressed that clinicians face when they care for patients with HIV/AIDS including: What ARV therapies should be preferentially chosen for initialtherapy and for those patients with ARV resistance? How to manage ARV therapy so as to minimize the risk ofHIV/AIDS-related and other complications. How to minimize the risk of ARV toxicities. Treatment options for hepatitis C coinfection. *This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings from CROI. Forward emailThis email was sent to nelsonvergel@... by newsletter@... | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114